Stockreport

Korro Reports Full Year 2024 Financial Results and Provides Business Updates

Korro Bio, Inc.  (KRRO) 
PDF —Completed dosing of first two cohorts in Phase 1/2a REWRITE Clinical Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD); Interim readout expected in the second [Read more]